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Introduction:  Brief  cognitive  tests  (BCT)  may  help  detect  cognitive  impairment  (CI)  in  the
clinical setting.  Several  BCT  have  been  developed  and/or  validated  in  our  country,  but  we  lack
specific recommendations  for  use.
Development:  Review  of  studies  on  the  diagnostic  accuracy  of  BCT  for  CI,  using  studies  con-
ducted in  Spain  with  BCT  which  take  less  than  20  minutes.  We  provide  recommendations  of  usePrimary  care;
Specialised  care
based on  expert  consensus  and  established  on  the  basis  of  BCT  characteristics  and  study  results.
Conclusion:  The  Fototest,  the  Memory  Impairment  Screen  (MIS)  and  the  Mini-Mental  State
Examination  (MMSE)  are  the  preferred  options  in  primary  care;  other  BCT  (Clock  Drawing  Test
[CDT], test  of  verbal  fluency  [TVF])  may  also  be  administered  in  cases  of  negative  results  with
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persistent  suspected  CI  or  concern  (stepwise  approach).  In  the  specialised  care  setting,  a  sys-
tematic  assessment  of  the  different  cognitive  domains  should  be  conducted  using  the  Montreal
Cognitive Assessment,  the  MMSE,  the  Rowland  Universal  Dementia  Assessment,  the  Adden-
brooke’s  Cognitive  Examination,  or  by  means  of  a  stepwise  or  combined  approach  involving
more simple  tests  (CDT,  TVF,  Fototest,  MIS,  Memory  Alteration  Test,  Eurotest).  Associating  an
informant questionnaire  (IQ)  with  the  BCT  is  superior  to  the  BCT  alone  for  the  detection  of  CI.
The choice  of  instruments  will  depend  on  the  patient’s  characteristics,  the  clinician’s  expe-
rience, and  available  time.  The  BCT  and  IQ  must  reinforce—–but  never  substitute—–clinical
judgement,  patient—doctor  communication,  and  inter-professional  dialogue.











Aplicación  práctica  de  los  test  cognitivos  breves
Resumen
Introducción:  Los  test  cognitivos  breves  (TCB)  pueden  ayudar  a  detectar  el  deterioro  cognitivo
(DC) en  el  ámbito  asistencial.  Se  han  desarrollado  y/o  validado  varios  TCB  en  nuestro  país,  pero
no existen  recomendaciones  específicas  para  su  uso.
Desarrollo:  Revisión  de  estudios  sobre  el  rendimiento  diagnóstico  en  la  detección  del  DC  lle-
vados a  cabo  en  España  con  TCB  que  requieran  menos  de  20  min  y  recomendaciones  de  uso
consensuadas  por  expertos,  sobre  la  base  de  las  características  de  los  TCB  y  de  los  estudios
disponibles.
Conclusión:  El  Fototest,  el  Memory  Impairment  Screen  (MIS)  y  el  Mini-Mental  State  Exami-
nation (MMSE)  son  las  opciones  más  recomendables  para  el  primer  nivel  asistencial,  pudiendo
añadirse  otros  test  (Test  del  Reloj  [TR]  y  test  de  fluidez  verbal  [TFV])  en  caso  de  resultado
negativo y  queja  o  sospecha  persistente  (aproximación  escalonada).  En  el  segundo  nivel  asis-
tencial es  conveniente  una  evaluación  sistemática  de  las  distintas  áreas  cognitivas,  que  puede
llevarse a  cabo  con  instrumentos  como  el  Montreal  Cognitive  Assessment,  el  MMSE,  el  Rowland
Universal Dementia  Assessment  o  el  Addenbrooke’s  Cognitive  Examination,  o  bien  mediante
el uso  escalonado  o  combinado  de  herramientas  más  simples  (TR,  TFV,  Fototest,  MIS,  Test  de
Alteración  de  la  Memoria  y  Eurotest).  El  uso  asociado  de  cuestionarios  cumplimentados  por  un
informador  (CCI)  aporta  valor  añadido  a  los  TCB  en  la  detección  del  DC.
La elección  de  los  instrumentos  vendrá  condicionada  por  las  características  del  paciente,  la
experiencia  del  clínico  y  el  tiempo  disponible.  Los  TCB  y  los  CCI  deben  reforzar  —–pero  nunca
suplantar—– el  juicio  clínico,  la  comunicación  con  el  paciente  y  el  diálogo  interprofesional.
































opulation  ageing  has  increased  the  prevalence  of  cognitive
mpairment  (CI)  and  dementia  associated  with  neurodegen-
rative,  vascular,  psychiatric,  or  other  medical  conditions,
any  of  which  are  modifiable.1,2 Early  diagnosis  is  vital,
s  professionals,  governments,  and  groups  involved  advo-
ate,  since  there  are  both  preventive  and  palliative
harmacological  and  non-pharmacological  treatments  which
an  significantly  reduce  the  personal,  family,  and  social
urden.3—6
Most  of  the  cases  of  dementia  are  preceded  by  an
bjectively  measured  cognitive  dysfunction  called  mild  CI
MCI).7—9 This  syndromic  entity,  although  aetiologically  het-
10rogeneous,  involves  a  high  risk  of  developing  dementia,
ut  it  also  offers  a  great  opportunity  to  assess  possible  pre-
entive  interventions.2 In  normal  clinical  practice,  patients




he  line  separating  MCI  and  dementia  is  not  clear.  There-
ore,  it  seems  logical  to  focus  diagnostic  efforts  towards  the
dentification  of  the  complete  CI  spectrum,  both  the  earliest
ariants  (MCI)  and  the  more  advanced  ones  (dementia).
A  recent  population-based  study  conducted  in  patients
lder  than  65  in  Spain  reported  a  prevalence  of  MCI  of  20%.11
espite  this  high  prevalence,  many  of  these  cases  are  still
o  be  diagnosed12 or  properly  registered,13 in  contrast  to
he  high  frequency  of  memory  loss  complaints  reported  in
edical  consultations.14 The  reasons  for  this  underdiagno-
is  could  be:  lack  of  access  or  time  during  consultations,
imited  training,  confidence  or  diagnostic  certainty  of  pro-
essionals,  lack  of  efficient  detection  tools,  or  inappropriate
se  of  these  tools.15When  MCI  is  suspected,  it  is  fundamental  to  first  rule
ut  confusional  syndrome  or  acute  or  subacute  (less  than
 months  of  progression)  focal  neurological  symptoms.
hese  symptoms  are  markedly  different  from  CI  (of  chronic
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ogy  are  unclear.22 We  have  not  assessed  either  telephoneFigure  1  Clinical  method  adapted  to  the  diagnosis  of  cogni
primary care  and  specialised  care.  *Specific  elements.
nature),  need  emergency  care  (usually  in-hospital),9 and
require  assessment  with  specific  tools.16 By  definition,  CI
must  be  detected  and  diagnosed  using  tests  that  assess
the  patient’s  cognitive  capacities  within  the  traditional
yet  irreplaceable  framework  of  the  clinical  method.17 The
information  provided  by  a  close  acquaintance  (regarding
cognitive  capabilities  and  performance  of  daily  activities)
and  the  results  on  the  mental  state  examination  (MSE)18 are
especially  important  for  the  clinical  method  (Fig.  1).
Excellent  review  studies  on  the  diagnostic  value  of  brief
cognitive  tests  (BCT)  for  detecting  dementia  have  been
conducted.19—21 However,  their  usefulness  in  detecting  CI
has  been  much  less  studied.21 The  aim  of  this  study  is
to  review  the  usefulness  of  BCT  and  offer  recommenda-
tions  on  their  rational  use  in  healthcare  settings  as  the  first
approach  to  patients  with  suspected  CI  or  cognitive  com-
plaints.  We  hope  to  aid  in  the  achievement  of  more  efficient
and  accurate  diagnoses  and  early  therapeutic  intervention
which  could  prevent  or  delay  development  of  dementia,  and
reduce  its  high  personal,  family,  and  social  costs.
Development
Methods
This  review  article  assesses  the  main  characteristics  of  BCT
and  offers  recommendations  for  use  in  clinical  practice.  In
general,  any  cognitive  test  which  takes  less  than  20  minutes
to  be  administered  is  a  BCT.  In  issuing  recommendations  for




Table  1  Definition  of  the  levels  of  care  used  in  this  article.
First  level  of  care  (PC)  
Definition  Area  of  medical  intervention,  pu
or  private,  which  the  patient  or  a
informant  visits  on  their  own
initiative
Professionals  involved  General  practitioners  and  nursesimpairment.  The  dotted  line  indicates  tasks  shared  between
ystems  are  organised:  first  level  or  primary  care  (PC)  and
econd  level  or  specialised  care  (SC).  The  first  level  of
are  normally  constitutes  patients’  first  encounter  with  the
ealthcare  system.  This  level  provides  outpatient  care  at  a
ealthcare  centre  or  at  the  patients’  home  and  also  includes
revention  and  early  detection  strategies.  The  second  level
rovides  care  to  patients  transferred  from  the  first  and
econd  levels  through  consultations,  admitted  patient
nits,  home-based  care  units,  and  emergency  services.
ealthcare  services  also  interact  with  other  social  and
ealthcare  institutions  that  provide  additional  care  services
r  cover  specific  needs  (medium-stay  hospitals,  day  care
entres,  institutions  for  the  elderly,  etc.).  Table  1  shows
he  definition  of  levels  of  care,  adapted  to  the  goals  of  this
tudy.
The  most  accessible  and  immediate  level  of  care  is  PC,
nd  professionals  at  this  level  have  a  longitudinal  perspec-
ive  of  the  patient  which  is  essential  for  detecting  CI,
specially  when  patients  have  a  high  education  or  intellec-
ual  level,  or  there  is  no  informant  available.  Professionals
t  the  SC  level  do  not  usually  have  previous  knowledge  of
he  patient.  However,  they  do  have  more  experience  and
esources  for  less  common  tasks.  PC  is,  therefore,  the  cor-
ect  level  for  detection  and  early  management  of  CI,  while
C  is  the  right  level  for  confirming  diagnoses,  determining
he  aetiology,  and  starting  specific  treatment.
This  article  does  not  address  systematic  detection  of
I  in  the  population,  since  this  process5 and  its  methodol-r  internet-based  cognitive  tests,  or  self-administered  tests
r  those  administered  by  a caregiver.  These  may  be  useful
ptions  for  patients  living  in  isolated  areas,  having  impaired
Second  level  of  care  (SC)
blic
n
The  patient  is  referred  by  another
professional,  from  any  speciality  or
healthcare  level,  due  to  suspicion  of
cognitive  impairment
 Neurologists,  psychologists,  geriatric






















Table  2  BCT  validation  studies  for  the  detection  of  CI  conducted  in  Spain.
BCT Scope No. of subjects
(CN/MCI/DEM)
COP  S Spec AUC Observations Reference
GIT (5 × 5) SC 192 (62/NS/NS) 19/20 0.89 0.82 0.94 Ferrero-Arias 200126
Clock drawing
test
SC  153 (66/21/66) 8/9 0.76 0.70 0.88 Score range: 0-10 Cacho 201027
PC 307 (131/112/64) 5/6 0.76 0.78 0.84a Score range: 0-7, consecutive
recruitment
Carnero-Pardo 201328
Mini-Cog PC 307 (131/112/64) 1/2 0.60 0.90 0.78a Consecutive recruitment Carnero-Pardo 201328
Episodic
memory test
SC 332 (152/115/65) 19/20 0.89 0.82 0.94 Amnestic-type MCI and dementia due
to AD
Ojea-Ortega 201325
Fototest SC 378 (225/58/95) 28/29 0.90 0.90 0.95 12% illiterate Carnero Pardo 200729





28/29  0.71 0.84 0.95 Multi-centre study Carnero-Pardo 201231
SC 407 (105/99/203) 28/29 0.83 0.96 0.93 Carnero Pardo 201332
MIS SC 120 (43/19/29) 4/5 0.92 0.81 0.92 76% with no primary studies Pérez-Martínez 200533
PC 140 (55/37/48) 4/5 0.73 0.87 NS Consecutive recruitment, was not
applied to 14% of illiterate patients
Carnero-Pardo 201130
M@T SC 88 (27/27/34) 36/37 0.93 1.00 0.99 Only amnestic-type MCI included Rami 200734
PC 139 (56/36/47) According to
level of
educationb
0.88 0.68 NS Consecutive recruitment, 14%
illiterate
Carnero-Pardo 201135
Eurotest PC 139 (56/36/47) 22/23 0.77 0.93 NS Consecutive recruitment, 14%
illiterate
Carnero-Pardo 201135
MMSE SC 91 (43/19/29) NS NS NS 0.86a MEC version (score range: 0-35) Pérez-Martínez 200533
SC 88 (27/27/34) 26/27 0.79 0.84 0.88a Only amnestic-type MCI included Rami 200936
SC 153 (66/21/66) 23/24 0.86 0.84 0.90 Cacho 201027
SC 194 (63/54/79) 25/26 0.90 0.68 0.90a Serial subtraction test was not
administered and the subject was
asked to  pick up the  paper with the
non-dominant hand.
Ferrero-Arias 200126
PC 360 (146/137/77) 22/23 0.77 0.77 0.84 Backward spelling test was not
administered
Carnero-Pardo 201337
MoCA SC 103 (21/51/31) 19/20 0.76 0.77 0.78 Lozano-Gallego
200938
RUDAS SC 115 (50/26/39) 21/22 0.83 0.86 0.90 Ramos-Rios 200939
ACE-III, Addenbrooke’s Cognitive Examination (3rd version); MCI, mild cognitive impairment; SC, specialised care; PC, primary care; AUC, area under the ROC curve; CN, cognitively normal;
CI, cognitive impairment; DEM, dementia; S, specificity; AD, Alzheimer disease; MEC, Mini-Examen Cognoscitivo; MIS, Memory Impairment Screen; MMSE, Mini-mental State Examination;
MoCA, Montreal Cognitive Assessment; NS, non-specified; COP, cut-off point; RUDAS, Rowland Universal Dementia Assessment; S, sensitivity; T@M, memory alteration test; BCT, brief
cognitive tests; GIT, general information test; FT, Fototest.
a BCT influence on diagnosis of cognitive impairment.























































Practical  application  of  brief  cognitive  tests  
mobility  or  other  health  problems,  or  with  little  motivation
to  go  to  a  clinic,  but  evidence  is  still  limited  as  to  their
efficacy.23—25 We  briefly  describe  BCTs  which  have  been  vali-
dated  for  detecting  CI  in  Spain,  and  offer  guidelines  for  their
use.  Tests  are  presented  according  to  their  administration
time  and  only  relevant  data  are  mentioned.  More  informa-
tion  on  the  characteristics,  method  of  administration,  and
diagnostic  yield  of  each  test  can  be  found  in  Table  2, as
well  as  in  the  validation  studies  mentioned  in  the  table,25—39
and  in  a  recently  published  monograph.40 To  make  compar-
isons  between  different  BCTs  easier,  we  have  described  only
diagnostic  accuracy  parameters  (sensitivity,  specificity,  and
the  area  under  the  ROC  curve  [AUC])  corresponding  to  the
cut-off  point  that  maximises  the  sum  of  the  sensitivity  and
specificity  values.
Brief  cognitive  tests
The  animal  category  fluency  trial  which  lasts  just  a  minute  is
the  briefest  dementia  detection  test  studied.41 It  addresses
linguistic  and  executive  skills  exclusively,  so  this  type  of  test
is  not  recommended  as  the  first  option  to  detect  CI.  Ver-
bal  fluency  tests  (VFT)  offer  extremely  useful  qualitative
and  quantitative  data  within  the  context  of  a  more  com-
prehensive  evaluation.  The  animal  naming  test  and  the  test
that  asks  the  patient  to  produce  as  many  words  beginning
with  ‘p’  in  a  minute  as  possible  are  the  most  recommended,
since  they  are  complementary  and  have  been  well  studied
in  Spain.42,43 There  are  some  variants,  such  as  the  Isaac
Set  Test44 and  the  general  information  test  or  the  five  by
five  test,26 which  make  administration  longer  and  more  dif-
ficult  without  improving  diagnostic  usefulness.  Therefore,
they  are  not  recommended  as  alternatives.
The  clock  drawing  test  (CDT)  assesses  visuospatial  ability
(VA)  and  executive  functions  (EF).45 Despite  the  appeal  of
its  simplicity  and  short  administration  time,  the  CDT  is  not
enough  in  and  of  itself  to  detect  CI,27 not  even  in  the  con-
text  of  PC28 (Table  2).  Nevertheless,  the  CDT  is  very  sensitive
to  damage  to  the  right  parietal  lobe  and  is  definitely  help-
ful  as  a  supplement  to  other  brief  tests,  especially  when  no
abnormal  performance  in  memory  tests  has  been  detected.
In  fact,  CDT  has  been  included  successfully  in  several  more
comprehensive  tests,  as  we  will  describe  later.  Its  main  dis-
advantage  is  that  minimum  drawing  skills  are  necessary  to
complete  the  test,  which  makes  the  CDT  inappropriate  as  a
tool  for  illiterate  patients  or  those  with  limited  graphomotor
skills.  There  are  several  proposals  for  scoring;  the  simplest
proposals  are  the  most  appropriate  for  detecting  CI  while
the  most  complex  may  be  more  useful  for  monitoring  studies
and  case  analysis.46,47
Mini-Cog  includes  the  most  frequently  affected  areas  at
CI  onset.  It  includes  a  3  word  learning  test  similar  to  the  Fol-
stein  Mini-mental  State  Examination  (episodic  memory  [EM]
and  CDT  [VA,  EF]).  Its  score  range  is  narrow  (0-5:  one  point
for  every  recalled  word,  and  2  additional  qualitative  assess-
ment  points  if  the  clock  has  all  numbers,  in  the  correct  order,
and  the  clock  hands  point  to  the  requested  time)  and  has  lit-
tle  sensitivity  for  detecting  CI28 (Table  2)  and  its  monitoring
study.  Mini-Cog  is  most  useful  in  supporting  a  diagnosis  of








The  episodic  memory  test  has  been  recently  created  and
alidated  in  a  sample  of  patients  with  amnestic-type  MCI
nd  Alzheimer  disease  (AD)25 (Table  2).  This  is  a  user-friendly
est  which  does  not  require  paper  or  pencil  (presumably  it  is
ittle  influenced  by  education  level).  It  exclusively  assesses
M  through  questions  regarding  the  recent  past.  Its  main
isadvantage  is  that  a  reliable  informant  must  be  present  to
orroborate  the  veracity  of  the  answers.
Fototest  comprises  a  visual-verbal  naming  task  with  6
hotographs  of  objects  (language),  a  verbal  fluency  task
language,  EF),  and  an  EM  task  with  free  and  cued  recall
f  the  previously  named  images.  Together  with  the  Folstein
ini-Mental  State  Examination  (MMSE),  Fototest  is  the  most
xtensively  studied  BCT  for  the  detection  of  CI  in  Spain.  This
s  a  widely  accepted  tool  that  in  both  PC  and  SC  has  shown
 satisfactory  usefulness  in  detecting  CI,  with  a  stable  cut-
ff  point  (28/29).29,31,32,35 Fototest  has  also  shown  a  higher
ost-effectiveness  ratio  than  MMSE  in  PC,  with  the  additional
dvantage  of  having  equivalent  parallel  versions  which  may
e  of  help  in  reducing  the  practice  effect  in  the  case  of
epeated  administrations  (PC,  follow-up)48 (Table  2).
The  Memory  Impairment  Screen  (MIS)  assesses  ver-
al  learning  (EM)  through  reading  and  subsequent  free
nd  cued  recall  of  4  words.  There  are  several  validation
tudies  conducted  in  Spain  that  have  shown  acceptable
esults  for  detecting  CI30,33 (Table  2)  and  good  results  for
ementia,30,33,49 especially  if  due  to  AD.50 The  MIS  also
resents  a  good  correlation  with  hippocampal  formation  and
ntorhinal  cortex  volumes,51 which  supports  its  potential  for
arly  detection  of  AD.
The  memory  alteration  test  (M@T)  includes  items  related
ith  EM  (free  and  cued  recall,  time  orientation)  and  gen-
ral  information  items  (long-term/semantic  memory  [SM])
o  a  lesser  extent.  These  characteristics,  together  with  the
ide  score  range  (0-50),  make  it  especially  appropriate  for
etecting  and  monitoring  the  first  clinical  stages  of  typical
D34,36 (Table  2).  The  M@T  distinguishes  between  subjective
emory  complaints  and  MCI,  and  has  been  validated  using
iochemical  and  neuroimaging  markers.52 Although  its  use-
ulness  in  PC  has  been  shown,35 limiting  this  test  to  SC  seems
ore  realistic  and  appropriate.
Eurotest  is  an  original  proposal  for  brief  cognitive  eval-
ation  that  uses  currency  coins  and  consists  of  3  parts:
nowledge  of  current  coins  (SM),  operations  with  coins  (cal-
ulation),  and  recall  of  the  coins  used  (EM).  Eurotest,  which
nables  to  some  degree  the  functional  evaluation  of  the  abil-
ty  to  handle  money,  has  obtained  acceptable  results  in  the
etection  of  CI35 (Table  2) and  good  results  for  dementia.53,54
t  is  an  ecologically  valid  test  applicable  to  illiterate  patients
hich  has  additionally  been  used  with  different  currency
ystems,  including  Chinese.
The  MMSE,  with  its  countless  adaptations  and
ranslations,55—59 is  the  most  widely  used  BCT  in  the
orld,  both  in  PC  and  SC  settings.  This  extensive  use,
hich  enables  the  comparison  and  follow-up  of  subjects
rom  different  origins,  has  2  main  disadvantages,  which
re  mainly  due  to  the  existence  of  multiple  versions  and
he  lack  of  clear  instructions  for  scoring60:  a  questionable
tandard  administration  procedure  and  unreliability.  Other
imitations  of  the  MMSE  are  the  limited  representation  of  EF,
hich  diminishes  its  sensitivity  in  detecting  MCI  and  fron-
















































































































ts  recent  copyright  licence.61 The  MMSE  has  been  tradition-
lly  employed  for  the  detection  of  dementia55,59,62,63;  most
f  the  information  regarding  its  usefulness  in  CI  detection
omes  from  validation  studies  of  other  tools  which  included
he  MMSE  as  a  comparison  test.  In  other  studies,  the
sefulness  of  the  MMSE  was,  in  general,  lower  than  that
f  the  tests  to  which  it  was  compared27,30,33,36 (Table  2).
n  the  only  specific  evaluation  study  of  the  MMSE  for  CI,
he  best  performance  was  obtained  with  a  lower  than  usual
22/23)  cut-off  point  (COP)  and  in  addition,  adjusting  for
ge  and  education  did  not  improve  its  discriminant  ability,
nlike  in  common  practice.28 In  any  case,  MMSE  helps  to
btain  qualitative  profiles  or  features  that  give  confidence
o  the  clinician  in  the  diagnosis  and  follow  up,  especially
n  the  case  of  patients  with  typical  AD.  Some  examples  are
he  selective  alteration  of  items  related  to  EM  (deferred
ecall,  day  of  the  month)  in  the  case  of  prodromal  AD,
ransformation  of  pentagons  into  quadrilaterals  in  AD  with
ild  dementia,  and  impaired  orientation  to  month  and
roblems  with  naming  a  pencil  in  the  case  of  moderate
D.
The  Montreal  Cognitive  Assessment  (MoCA)  has  an  eclec-
ic  and  balanced  design  for  the  detection  of  MCI  regardless  of
etiology.  It  includes  items  regarding  attention,  free  recall
list  of  5  words),  EF  (Trail  Making  Test,  similarities),  calcu-
ation,  VA  (copy  a  cube,  CDT),  orientation,  and  language.
he  first  validation  studies,  conducted  in  Canada,  obtained
romising  results.64 However,  a  Spanish  study  showed  a
ower  effectiveness  in  the  detection  of  MCI  (69%  of  the  sub-
ects  were  correctly  classified  vs  90%  in  the  original  study)38
Table  2).  Education  level  exerts  a  strong  influence  on  the
oCA,  as  was  shown  in  validation  studies  conducted  in  other
ountries.
The  Rowland  Universal  Dementia  Assessment  (RUDAS)
as  developed  in  Australia  for  its  administration  to  multicul-
ural  and  illiterate  populations.  It  assesses  identification  of
ody  parts,  EM,  visuoconstructive  praxis  (drawing  a  cube),
nd  reasoning.  A  preliminary  study  conducted  in  Spain
btained  good  results  in  the  detection  of  CI39 (Table  2).
There  are  2  BCTs  which  have  been  validated  in  non-
linical  community  settings  and  which  therefore  do  not  meet
nclusion  criteria  in  this  review  article.  However,  we  mention
hem  here  since  they  can  be  useful  in  PC.
The  Abbreviated  Mental  Test  (AMT)  by  Hodkinson  assesses
rientation,  attention,  and  memory.  The  test,  which
ncludes  10  items,  is  easy  to  administer  (except  the  item
equiring  the  identification  of  2  people),  and  education  level
s  less  influential.  A  COP  of  7/8  showed  a  good  performance
n  the  detection  of  MCI65 and  dementia.66 The  AMT  is  rarely
sed  in  Spain,  possibly  due  to  its  limited  distribution  and
vailability.
The  Leganés  cognitive  test  (LCT)  was  designed  to  assess
he  cognitive  capacities  of  an  elderly  population  with  a  low
evel  of  education.67 It  yielded  excellent  results  for  the
etection  of  dementia  (COP  22/23)  and  good  for  CI  (COP
6/27).68 Since  most  of  its  items  are  related  to  EM,  the  LCT
an  be  useful  for  detecting  and  monitoring  typical  AD  when
dvanced  age,  low  education  level,  or  other  circumstances
dvise  against  administering  more  complex  tests.
Other  commonly  used  BCTs  in  Spain  which  have  been
pecifically  evaluated  for  use  with  dementia  although  not
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The  Pfeiffer  questionnaire  (Short  Portable  Mental  Sta-
us  Questionnaire  [SPMSQ])  is  similar  to  the  AMT,  although
ore  focused  on  SM.  Mistakes  instead  of  correct  answers  are
cored.  The  SPMSQ  obtained  good  results  in  the  detection  of
ementia  in  PC69 and  SC  (COP  2/3),70 and  excellent  results
n  geriatric  settings  (COP  4/5).71
The  7  Minute  Screen  (7MS),  which  requires  somewhat
ore  than  7  minutes  to  administer,  presents  some  charac-
eristics  (16  figure  learning  task,  complex  score  system)  that
ake  it  difficult  to  use  as  a  first  approach  to  CI  in  the
ealthcare  setting.  However,  being  halfway  between  MSE
nd  formal  neuropsychological  examination  (Fig.  1),  it  can
e  a  useful  tool  in  the  assessment  of  cognitive  areas  usually
mpaired  in  AD.  The  7MS  achieves  an  excellent  performance
n  the  detection  of  dementia  (COP  20/21),70,72 but  an  Argen-
inian  study  has  questioned  its  usefulness  in  MCI.73
The  Addenbrooke’s  Cognitive  Examination  (ACE)  was
eveloped  from  the  MMSE,  adding  frontal/executive  and
isuospatial  elements.  Its  third  version  (ACE-III)  is  currently
vailable  and  has  shown  good  results  with  regards  to  demen-
ia  detection,74 and  excellent  results  with  subjects  with
ore  than  9  years  of  schooling  (COP  73/74).  The  ACE  can
lso  be  useful  in  distinguishing  the  main  aetiological  types  of
ementia.75 An  abbreviated  version  has  been  recently  val-
dated  (M-ACE)  which  may  have  more  discriminant  ability
han  the  original  version.76
imits  of  the  brief  cognitive  tests:  new  action  and
esearch lines
ithout  questioning  its  usefulness  and  convenience,  the
iagnostic  capability  of  BCT  is  far  from  being  completely
atisfactory,  especially  regarding  the  detection  of  CI.  One
olution  would  be  adding  more  items  and  areas  in  order  to
est  more  cognitive  skills  with  more  detail,  but  then  the
est  would  become  less  efficient  and  require  more  time  and
pecialised  personnel.  In  that  case  the  screening  tool  and
he  gold  standard  would  be  nearly  the  same.  Another  pos-
ible  solution  might  consist  of  using  more  complex  tasks
nvolving  diverse  cognitive  skills,  including  processing  speed
divided  attention  tasks,  figural  fluency,  etc.).77 However,  a
ore  complex  and  difficult  task  is  likely  to  lead  to  greater
nfluence  by  non-pathological  factors  (ageing,  stress,  etc.),
hereby  reducing  specificity.  Using  questionnaires  on  cog-
itive  complaints  or  metacognition  is  another  option,  but
his  has  been  demonstrated  as  less  than  useful  due  to  the
nfluence  of  lesion  topography,  psychiatric  comorbidity,  and
sychological  and  social  factors.78
Informant  questionnaires  are  generally  simple,  easy  to
dminister  tools  that  offer  a  perspective  (longitudinal  and
hat  of  the  informant)  supplementary  to  the  one  offered  by
ognitive  tests.79 The  Informant  Questionnaire  on  Cognitive
ecline  in  the  Elderly  (IQCODE)  or  informant  test  is  the
ost  widely  studied  questionnaire  in  Spain.  Both  the
omplete  version  (26  items)  and  the  abbreviated  version
17  items)  have  shown  a  good  performance  in  the  detection
f  dementia,80—82 achieving  an  AUC  of  0.91  in  one  of  the
tudies.82 Furthermore,  this  questionnaire  is  not  influenced
y  age,  sex,  mental  health,  or  prior  intellectual  level.62
erformance  of  the  IQCODE  for  the  detection  of  CI  was




























Advantages  Disadvantages  Guidelines  for  use Scope  Restrictions  on  use Accessibility
VFT  1  L,  EF  Very  user-friendly  It  does  not  assess









2 EF,  VA User-friendly,
helpful  to  locate
the  lesion
It  does  not  assess







PC,  SC No  restrictions  or
licenses
Mini-Cog 3  EM,  EF,  VA Multi-domain  The  score  range  is




PC  No  restrictions  or
licenses







PC  No  restrictions  or
licenses
SPMSQ 3  EM,  SM,  A  Applicable  to
illiterate  patients
Prior  data  should
be  known.  It  is  not
validated  for  CI
Detection  of
dementia
PC  No  restrictions  or
licenses
www.hipocampo.org
Fototest  3  EM,  EF,  L  Applicable  to
illiterate  subjects.
It  assesses  free
and  cued  recall.
Parallel  versions




follow-up  of  CI
and  dementia







MIS 4  EM  Free  and  cued
recall  assessment
Reading  is  needed.
It  only  assesses
memory
Detection  of  CI  PC  Copyright-limited
use
M@T 6  EM,  SM  Applicable  to
illiterate  subjects.
It  assesses  free
and  cued  recall,
and  SM





and  typical  AD










It  requires  a
minimum  visual
acuity  and  having
coins  at  hand
Detection  and
follow-up  of  CI
and  dementia





MMSE  10  EM,  SM,  EF,
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and  dementia































Advantages  Disadvantages  Guidelines  for  use  Scope  Restrictions  on  use  Accessibility
LCT  11  EM,  L,  A,  SM  Applicable  to  the
elderly  and
illiterate  subjects
It  does  not  assess
EF  or  VA.  Limited
distribution
Detection  and
follow-up  of  CI
and  dementia
PC  No  restrictions  or
licenses
MoCA 12  EM,  SM,  EF,








follow-up  of  CI
and  dementia




7MT  13  EM,  EF,  L,  VA  Standardised
scoring  with  a
wide  range
Scrupulous
scoring.  It  requires














follow-up  of  CI
and  dementia





asp  (in  English)
ACE-III 16  EM,  SM,  EF,














follow-up  of  CI
and  dementia  of
different  profiles







A, attention; ACE-III, Addenbrooke’s Cognitive Examination (3rd version); SC, specialised care; AMT, Abbreviated Mental Test; PC, primary care; VA, visuospatial area; NS, numerical
skills; CI, cognitive impairment; FTLD, frontotemporal lobar degeneration; AD, Alzheimer disease; EF, frontal/executive functions; L, language; EM, episodic memory; MEC, Mini-Cog;
min, minutes; MIS, Memory Impairment Screen; MMSE, Mini-mental State Examination; MoCA, Montreal Cognitive Assessment; SM, remote/semantic memory; LCT, Leganés cognitive test;
RUDAS, Rowland Universal Dementia Assessment; SPMSQ, Short Portable Mental Status Questionnaire; M@T, Memory alteration test; VFT, verbal fluency test (animals, words beginning















































Practical  application  of  brief  cognitive  tests  
added  predictive  value  to  the  MMSE  (AUC  0.86  vs  0.82  with
MMSE  only).  The  Functional  Activities  Questionnaire  (FAQ)
comprises  11  items  and  has  also  obtained  good  results  in
the  detection  of  dementia  (AUC  0.91),  although  results
are  poorer  for  detecting  CI  (AUC  0.77).  The  FAQ,  like
the  IQCODE,  improved  the  performance  of  the  MMSE  for
detecting  dementia  (AUC  0.95  vs  0.91  with  MMSE  only).83
The  Ascertain  Dementia-8  (AD  8)  is  a  very  brief  proposal,
designed  for  PC.  It  includes  8  yes  or  no  questions  and
presents  a  good  performance  for  diagnosing  CI  (AUC  0.90).
Furthermore,  its  use  associated  with  a  BCT  (Fototest)  adds
predictive  value  (AUC  of  Fototest  0.93  vs  AUC  of  Fototest
plus  AD  8  0.96).32
Physical  examination  (motor  alterations,  frontal  signs,
etc.)  or  biological  sample  analysis  (blood,  saliva,  etc.)  could
provide  other  complementary  markers  for  the  detection
of  CI.  But  these  lines  of  research,  though  interesting  for
aetiological  diagnosis,  have  not  yet  provided  evidence  of
practical  usefulness.84,85
Conclusions
A  first  approach  to  the  patient  with  complaint  or  suspicion  of
CI  should  at  minimum  include  the  examination  of  the  more
frequently  impaired  areas  (EM  and  EF).  In  PC  we  recommend
using  some  BCT  as  that  could  offer  objective  support  to  the
clinical  suspicion  and  facilitate  an  efficient  referral  to  SC  to
obtain  an  accurate  diagnosis.  Fototest  and  MIS  have  been
well  studied  and  are  the  most  recommended  options  for
PC.  Other  tests  (CDT,  VFT)  can  be  added,  especially  in  the
case  of  negative  results  and  persistent  complaints  or  suspi-
cions  (stepped-care  approach).  Eurotest  and  MMSE  are  also
valid  alternatives  in  PC,  depending  on  the  circumstances
(Eurotest  for  illiterate  patients  and  MMSE  if  more  time  is
available)  (Table  3).  The  patient’s  performance  in  his  or
her  day-to-day  social  environment  should  be  clearly  defined
both  in  PC  and  SC  (money  handling,  medication,  etc.).  If
impairment  is  observed,  suspicion  of  dementia  and  not  of
MCI  should  be  considered.
A  systematic  review  of  the  main  cognitive  areas  (atten-
tion,  language,  EM,  EF,  VA)  must  be  conducted  in  SC,  so  a
formal  neuropsychological  examination  would  be  the  ideal
test  (Fig.  1).  For  this  reason,  the  most  recommended  tools
for  this  level  of  care  are,  theoretically,  those  permitting
evaluation  of  the  highest  number  of  cognitive  domains,
such  as  MoCA,  MMSE,  RUDAS,  or  ACE-III.  These  tests  should
be  selected  according  to  patient  characteristics  (MoCA  if
the  patient  is  close  to  normality,  MMSE  if  advanced  CI  is
suspected,  RUDAS  if  the  patient  is  illiterate,  ACE-III  if  in
doubt  between  AD  and  frontotemporal  lobar  degeneration),
the  clinician’s  experience,  and  the  available  time  (ACE-III
administration  requires  more  than  15  minutes).  Maybe  due
to  the  lack  of  specific  studies  (ACE-III),  modest  or  negative
results  available  (MMSE,  MoCA),30,38 or  the  presence  of  other
disadvantages  (MMSE  is  not  free),60,61 it  is  still  to  be  deter-
mined  whether  the  use  of  these  tools  is  more  efficient  than
the  use  of  other  brief  and  simple  cognitive  tests.  This  deter-
mination  should  consider  that  tests  can  be  administered
separately  (MIS,33 M@T,36 and  Fototest30),  combined  (VFT,
CDT,  and  MMSE)27,28 or  in  a  stepped-care  approach  (Fototest PRESS
9
nd  Eurotest),86 particularly  in  situations  with  little  time
vailable.
Possible  actions  to  avoid  false  negatives  are  varied  and
fficacious,  and  implementable  in  developed  countries  with
nough  healthcare  and  social  resources.  These  include  pro-
oting  a  healthy  lifestyle,  controlling  vascular  risk  factors,
dvising,  researching,  etc.  These  measures  are  not  risky
r  costly,  and  all  of  them  can  be  addressed  or  monitored
y  PC.  Using  cut-off  points  other  than  those  recommended
s  acceptable  in  order  to  increase  sensitivity  and  facilitate
arly  detection,  especially  in  cases  of  persistent  complaint
r  suspicion  or  in  subjects  with  a  prior  high  intellectual  level.
ut-off  points  serve  as  a  guide  and  support,  but  never  as
onfirmation  of  the  diagnosis  of  CI,  which  is  obtained  by
linically  assessing  all  the  information  available  (Fig.  1).
To  diagnose  dementia,  informant  questionnaires  perform
he  same  or  even  better  than  BCT.  This  is  most  likely  because
 large  number  of  older  people  in  Spain  have  a  low  level  of
chooling,  resulting  in  lower  specificity  of  cognitive  tests.
owever,  an  MSE  should  be  performed  whenever  possible,
ince  the  target  is  CI  (MCI  or  dementia)  and  the  informant’s
erceptions  might  not  be  valid,  or  might  be  distorted  by
rimarily  non-cognitive  aspects  (physical  health,  sensory
eficit,  etc.),  or  even  self-interest.  Informant  question-
aires  provide  added  value  to  BCT,  and  this  synergy  should
e  further  investigated.  Rigorous,  non-stop  and  imaginative
esearch  here  in  Spain  has  led  to  the  designing  of  varied
nd  complementary  BCT,  which  are  useful  to  increase  cli-
icians’  confidence  and  accuracy  in  their  first  approach  to
he  patient  with  complaint  or  suspicion  of  CI.  The  recom-
ended  BCT  as  well  as  their  cut-off  points  and  instructions,
ust  be  accessible  in  the  electronic  medical  histories  in
C  and  SC  when  possible  in  order  to  facilitate  use  and
ake  it  more  cost-effective.  BCT  potential  should  be  further
xplored,  especially  regarding  aetiological  diagnosis  (for
xample,  Eurotest  may  help  detect  CI  caused  by  anything
ther  than  typical  AD)87 and  its  usefulness  in  progression
onitoring.  Tests  and  questionnaires  should  reinforce  but
ever  replace  medical  opinion,  fluid  communication  with
atients  and  their  acquaintances,  coordination  between  the
ifferent  healthcare  levels,  and  dialogue  between  profes-
ionals  in  healthcare  settings.
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